Ivabradine Glenmark

Ivabradine, the active ingredient in Ivabradine Glenmark, is a If channel inhibitor presented as a tablet for oral use. It lowers heart rate and is indicated for chronic stable angina and heart failure with reduced ejection fraction in adult patients.

GNH USA supplies Ivabradine Glenmark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Customers benefit from consistent product availability and regulatory support across multiple markets.

Ivabradine acts on the cardiac If channel to reduce heart rate, providing therapeutic benefit in specific cardiovascular conditions.

- Chronic stable angina: reduces the frequency of angina attacks and improves exercise tolerance. - Heart failure with reduced ejection fraction: lowers heart rate, contributing to improved ventricular remodeling and reduced hospitalization risk. - Symptomatic angina (exercise‑induced): enhances functional capacity by decreasing myocardial oxygen demand.

Ivabradine may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Bradycardia: resting heart rate may fall below 50 bpm. - Visual disturbances (phosphenes): transient luminous phenomena. - Headache: mild to moderate intensity. - Dizziness: often related to reduced heart rate. - Fatigue: general feeling of tiredness.

Serious or Rare Side Effects: - Severe bradycardia: may require medical intervention. - Atrial fibrillation: irregular heart rhythm episodes. - Symptomatic hypotension: dizziness or fainting due to low blood pressure. - Vision loss: rare but potentially permanent ocular events. - Allergic reactions: rash, pruritus, or anaphylaxis.

When prescribing Ivabradine, clinicians should consider several safety precautions to minimize risk.

- Monitor heart rate: ensure resting heart rate remains above 50 bpm before initiation. - Avoid in severe hepatic impairment: limited metabolism may increase systemic exposure. - Use caution with concomitant beta‑blockers: additive heart‑rate lowering effect can cause profound bradycardia. - Do not use in patients with sick sinus syndrome or second‑degree AV block: risk of severe conduction disturbances. - Store at ambient temperature: keep in the original pack, protect from moisture.

Ivabradine can interact with other medicines, altering its plasma concentration or additive pharmacodynamic effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase Ivabradine levels and risk of bradycardia. - Other heart‑rate‑lowering agents (e.g., beta‑blockers, digoxin): can cause excessive slowing of heart rate.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce Ivabradine exposure. - Verapamil: modest increase in Ivabradine plasma concentration. - Diltiazem: may elevate Ivabradine levels, requiring heart‑rate monitoring.